Illumina, Inc. (NASDAQ:ILMN) Position Increased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 25.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,892 shares of the life sciences company’s stock after purchasing an additional 591 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Illumina were worth $403,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ILMN. Clear Creek Financial Management LLC boosted its holdings in Illumina by 6.3% in the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock worth $236,000 after purchasing an additional 100 shares in the last quarter. Lido Advisors LLC boosted its holdings in shares of Illumina by 6.1% during the 3rd quarter. Lido Advisors LLC now owns 1,859 shares of the life sciences company’s stock worth $255,000 after buying an additional 107 shares during the period. Quent Capital LLC raised its holdings in Illumina by 45.2% in the 4th quarter. Quent Capital LLC now owns 363 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 113 shares during the period. ICICI Prudential Asset Management Co Ltd lifted its position in Illumina by 9.4% during the 4th quarter. ICICI Prudential Asset Management Co Ltd now owns 1,541 shares of the life sciences company’s stock worth $215,000 after acquiring an additional 133 shares during the last quarter. Finally, Perigon Wealth Management LLC boosted its holdings in Illumina by 3.3% during the fourth quarter. Perigon Wealth Management LLC now owns 4,414 shares of the life sciences company’s stock valued at $615,000 after acquiring an additional 142 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ILMN shares. Royal Bank of Canada reissued an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a research report on Tuesday, April 9th. OTR Global reissued a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Stephens reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Illumina in a report on Tuesday. HSBC cut Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, Barclays lifted their price target on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Illumina presently has a consensus rating of “Hold” and a consensus price target of $164.65.

Illumina Trading Up 0.7 %

Shares of NASDAQ ILMN traded up $0.73 during midday trading on Thursday, hitting $111.35. The stock had a trading volume of 1,753,761 shares, compared to its average volume of 1,740,195. The company’s 50-day simple moving average is $128.53 and its 200 day simple moving average is $126.83. The firm has a market cap of $17.74 billion, a P/E ratio of -13.66 and a beta of 1.20. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $213.91. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.05. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.08 EPS. Research analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Jacob Thaysen purchased 7,330 shares of the stock in a transaction on Thursday, February 22nd. The shares were purchased at an average price of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.17% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.